Older biological age is associated with adverse COVID-19 outcomes: A cohort study in UK Biobank

Introduction

Older chronological age has emerged as the most powerful risk factor for severe infection, requiring hospitalisation or critical care, and mortality from coronavirus disease 19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).^1,2 One potential mediator of this effect is ageing of the immune system, leading to increased levels of pro-inflammatory senescent cells and reduced proliferative capacity of immune precursor cells.^3,4 Whether an individual’s biological age, which may be older or younger than their chronological age, plays an additional role in COVID-19 outcome is unclear. Telomere length (TL), a proposed marker of biological age, is a key determinant of proliferative capacity and cellular lifespan, triggering senescence once a critically short TL is reached.⁵ Although TL − commonly measured in leucocytes (LTL) − declines with chronological age, age accounts for only ∼3.5% of the inter-individual variation in LTL.⁶

A few small case-control studies, in which LTL was measured after SARS-CoV-2 infection at the time of hospital admission, have reported associations of shorter LTL with hospitalisation and severe outcomes.⁷⁻⁹ However, their interpretation is complicated by the possibility that LTL measurements could have been influenced by white cell turnover in response to infection. To our knowledge, no study to date has reported on associations of prior (pre-infection) LTL values and adverse COVID-19 outcomes.

Here, we examine whether LTL measured several years prior to SARS-CoV-2 infection is associated with adverse COVID-19 outcomes, leveraging our recent completion of LTL measurements in 474,074 participants aged 40-69 at time of recruitment into UK Biobank (UKB)⁶ between 2006 and 2010.^{10, 11}

Methods

Results

By 30 November 2020, 914 participants were identified with an adverse COVID-19 related outcome and 5861 participants were identified as primary controls (positive community test for COVID-19 but not hospitalised). Their characteristics are summarised in Table 1. On average, compared to controls, cases were older and more likely to be male and from a non-White background. At time of their entry into UKB, they also had a higher BMI and more likely to be current smokers. (Table 1).

LTL at entry to UKB was on average shorter in cases compared with controls (Table 1). The OR for the primary outcome was 1.17 (95% CI 1.05-1.31; P=0·004) per 1-SD shorter usual LTL, after adjustment for chronological age, sex and ethnicity (Table 2). The OR only slightly attenuated after further adjustment for smoking status and BMI (OR=1·15, 1·03-1·28), and after adjustment for the presence of any of 123 diseases recorded at baseline (OR=1·14, 1·02-1·27). As expected, older chronological age, male sex and non-White ethnicity were each associated with higher risk of adverse COVID-19 outcomes independently of usual LTL (Table 2).

Sub-components of our study’s primary composite outcome were not mutually exclusive, as 46 cases contributed to all four sub-components (Figure 1). Shorter usual LTL was significantly associated with higher risk of each sub-component (Table 2). ORs were broadly similar to the main findings in analyses that replaced the SARS-CoV-2-positive control group with all UKB participants as controls or that excluded any participant with a hospital admission in the six months prior to testing positive for SARS-CoV-2 (Table 2).

• Download figure
• Open in new tab

Figure 1. Venn diagram showing the distribution of the individual components of the primary outcome.

Hosp., hospitalised due to COVID-19; CC, critical care admission due to COVID-19; Resp. sup, need for respiratory support; Death, death due to COVID-19.

In MR analyses, the IVW odds ratio was 1·48 (0·79-2·77; P=0·224) per 1-SD shorter genetically-determined LTL, a non-significant result directionally concordant with the observational finding (Table 2). Results were similar using the weighted median method (Table 2) and there was no evidence of horizontal pleiotropy (MR-Egger intercept P=0·591).

Discussion

In a study of 6,775 participants with a positive test for SARS-CoV-2 (nested within the 500,000-participant UKB), we have shown that individuals with shorter LTL assessed several years prior to SARS-CoV-2 infection had higher risk of adverse COVID-19 outcomes, even after adjustment for several established risk factors for COVID-19 including chronological age. This finding suggests that being “biologically” older is likely to be independently associated with COVID-19 hospitalisation and severity. The results of analysis of LTL-associated genetic variants and COVID-19 were directionally concordant with our observational findings but non-significant. Our results, therefore, encourage further investigation of the potential causal relevance of biological ageing to adverse COVID-19 outcomes.

The validity of our results is supported by several observations. First, our study confirmed well-known associations of older chronological age, male sex, and non-White ethnicity with adverse COVID-19 outcomes.² Each of these factors was associated much more strongly with COVID-19 outcomes than was shorter LTL. Second, we found significant associations of shorter LTL with each sub-component of our study’s primary composite outcome. Third, our main findings persisted after adjustment for multiple risk factors. Fourth, our overall result was robust to sensitivity analyses designed to minimise the scope for potential biases. For example, collider bias can lead to false associations between a risk factor and an outcome,¹⁴ as highlighted by studies related to understanding of COVID-19 disease risk and severity.¹⁵ Indeed, we found evidence for potential colliders in our own analysis, observing a small but significant association between shorter LTL and higher likelihood of SARS-CoV-2 testing. Hence, we only included participants with a positive SARS-CoV-2 test outside the hospital setting, as hospitalisation itself may increase the likelihood of testing.

The biological mechanisms through which shorter LTL might increase risk of adverse outcomes from SARS-CoV-2 infection remain to be clarified. Our finding that the association was not substantially attenuated when we adjusted for the association of LTL with multiple diseases at baseline, suggest that, if this association is causal,, it is probably not simply a reflection of co-morbidity due to the impact of shorter LTL on risk of these diseases. A potential mechanism relates to the impact of telomere length dynamics on aging of the immune system¹⁹ and the potential role of senescence in severe SARS-CoV-2 infection.^3,4,20 When challenged with infection, individuals with shorter LTL prior to infection would have less proliferative capacity and be more likely to accrue high levels of senescent cells more quickly than individuals with longer LTL.²¹ Individuals with shorter LTL may therefore potentially already harbour a higher proportion of senescent T-cells, reducing the number of functional cells that are able to respond to infection.²⁰ Additionally, senescent cells are known to adopt a pro-inflammatory phenotype, secreting high levels of cytokines, which can further drive inflammation in COVID-19 patients.²⁰

Our study has several limitations. UKB is not representative of the general UK population; only 6% of those invited to participate did so.²² Risk factor levels and mortality rates are lower than in the general population, although risk factor associations with mortality for a range of diseases are similar.²³ Hence, further studies are warranted in other populations. Our one-sample Mendelian randomisation analysis in UKB had limited power to reliably estimate causal effects as fewer than one thousand participants had been hospitalised after a positive SARS-CoV-2 test and our genetic instrument of 131 variants, while using the most up to date information on LTL-associated variants, accounts for only ∼4% of inter-individual variation in LTL.¹¹ While there are data from large genetic studies of COVID-19²⁴, they could not be used in our analysis because the outcome definitions differed substantially from those we used, and because of their inclusion of within hospital testing that is potentially a collider with LTL and COVID-19 outcomes. Larger sample sizes with comparable disease phenotypes should, therefore, enable more precise evaluation of a potential causal association between shorter LTL and adverse COVID-19 outcomes.

In conclusion, in the largest study to date, we provide evidence that shorter LTL, reflecting older biological age, is associated with higher risk of adverse COVID-19 outcomes, independent of several major risk factors for COVID-19.

Data sharing

Source data is accessible via application to the UK Biobank.

Author Contributions

V.C., C.P.N., J.N.D., S.E.P., N.C.H. and N.J.S. conceived the project. All authors contributed to the sample definition and the analysis plan. Q.W., C.M. and C.P.N. performed the analyses. V.C., C.P.N., Q.W. and N.J.S. prepared the manuscript and all authors revised it. V.C., C.P.N., J.R.T., J.N.D. and N.J.S. (Principal investigator) secured funding and oversaw the project.

Competing Interests Declaration

The authors declare no competing interests.

Data shown are mean (SD) for continuous traits or n (%) for categorical traits. LTL, smoking status, BMI, sex and ethnicity are from baseline information. LTL is log-transformed and Z-standardised.